Is Acalabrutinib launched in China?

Acalabrutinib (Acalabrutinib) is a new generation of targeted therapy drugs that belongs to the category of brutinib (BTK) inhibitors. As an oral small molecule compound, acotinib is mainly used to treat malignant tumors such as hematological B cell lymphoma.

Acotinib has been launched in China, but it has not yet been included in medical insurance. Since it has just been launched, it is still difficult for patients to purchase it domestically. They need to purchase acotinib through overseas channels. The cheaper ones abroad are mainly generic drugs, mainly Bangladeshi generic drugs. The price is around 6,000 to 7,000, and the ingredients of original drugs and generic drugs are basically the same.

Acotinib works by selectively inhibiting BTK, a key enzyme in the B cell signaling pathway. This pathway plays an important role in the activation, proliferation and survival ofB cells. By blocking BTK, acotinib inhibits the abnormally activated B cell signaling pathway and slows down or inhibits the growth and spread of malignant tumor cells.

Acotinib is primarily approved for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is typically used as monotherapy in patients with untreated chronic lymphocytic leukemia or as an alternative treatment in patients with chronic lymphocytic leukemia who have failed to respond to other treatments.

Compared with traditional chemotherapy drugs, the advantage of acotinib is its high selectivity. It interferes with specific signaling pathways in cancer cells more precisely, reducing the adverse effects on normal cells, thus reducing the incidence of toxic side effects.

Acotinib demonstrated good safety and tolerability in clinical trials. Compared with some traditional BTK inhibitors, acotinib has better selectivity, which means that patients are more likely to tolerate treatment and reduce some common adverse reactions.